ROTH MKM initiated coverage of TriSalus Life Sciences with a rating of Buy and set a new price target of $11.00

Northland Capital initiated coverage of TriSalus Life Sciences with a rating of Outperform and set a new price target of $12.50

Oppenheimer initiated coverage of TriSalus Life Sciences with a rating of Outperform and set a new price target of $10.00

Canaccord Genuity initiated coverage of TriSalus Life Sciences with a rating of Buy and set a new price target of $12.00

4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)

TriSalus Life Sciences® Inc. ("TriSalus" or the "Company") (NASDAQ:TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced delivery technology and novel immunotherapy, nelitolimod, has announced the addition of Riad Salem, M.D., to its Scientific Advisory Board (SAB). Dr. Salem is the Chief of Interventional Radiology, and a Professor of Radiology, Surgery, and Medicine in Chicago. Mary Szela, Chief Executive Officer and President of TriSalus, stated, "We are thrilled to welcome Dr. Salem to our SAB. His pioneering work in radiological research and leadership in developing innovative treatments for liver cancer and other

– Accomplished industry veteran brings deep strategic and operational expertise TriSalus Life Sciences® Inc. (NASDAQ:TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today the appointment of Liselotte Hyveled to its Board of Directors. Ms. Hyveled brings over two decades of experience stimulating scientific innovation and advancing pharmaceutical pipelines through research and development excellence. "We are thrilled to welcome Liselotte to the TriSalus Board of Directors as we commercialize the TriNav® Infusion System and progress our pipeline through key milestones in

Devlin Brings Significant Expertise in Commercialization, Sales and Marketing TriSalus Life Sciences® Inc., (TriSalus or the Company), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced that Jodi Devlin has joined the Company as President of TriSalus Therapeutics. In this newly established role, Ms. Devlin will be responsible for developing and executing the go-to-market strategy for TriSalus' SD-101 therapeutic candidate, building the Company's therapeutic marketing operations, working with the clinical team to incorporate commercial and payor needs into the clinical stra

– Reported Q3 and nine-month revenues of $7.3 million and $21.2 million respectively, up 42% and 66% year-over-year – Provided 2025 guidance with expectations of over 50% annual sales growth, 20%+ reduction in operating expenses, positive full-year EBITDA, and positive cash flow in H2 2025 – Launched TriNav® LV Infusion System and TriGuide™ Guiding Catheter for larger vessels and complex cases, expanding the TriNav system's full access to the $375 million embolization market – Initiated the PROTECT registry trial using the TriNav system to treat multinodular goiters, expanding the TriNav system's reach into the $400 million thyroid embolization market – Presented positive Phase 1 da

TriSalus Life Sciences® Inc. ("TriSalus" or the "Company") (NASDAQ:TLSI), an oncology company dedicated to enhancing outcomes for patients suffering from liver cancer through its advanced delivery technology as well as an investigational immunotherapy, nelitolimod, has announced a strategic partnership with Geo-Med, LLC ("Geo-Med"), a certified Service-Disabled Veteran-Owned Small Business (SDVOSB), to expand availability of the TriNav Infusion System ("TriNav") to U.S. Department of Veterans Affairs (VA) medical centers nationwide. "Fittingly, on the day honoring our veterans, we announce this pivotal collaboration designed to expand access for U.S. veterans to our proprietary Pressure-En

TriSalus Life Sciences® Inc. ("TriSalus" or the "Company") (NASDAQ:TLSI), a leader in oncology innovations integrating advanced delivery technology to transform treatment for liver and pancreatic tumors, today announced the launch of the TriNav® LV Infusion System and TriGuide™ Guiding Catheter. These new devices are designed to optimize therapeutic delivery, enhancing treatment options and potentially improving outcomes for patients. Highlights of the Launch: Expanded Patient Access: The TriNav LV Infusion System is tailored for larger vessels (3.5-5.0 mm), increasing the number of patients eligible for TriSalus' proprietary Pressure-Enabled Drug Delivery (PEDD™) technology. Comprehen

Call Scheduled for Thursday, November 14, 2024, at 9:00 a.m. ET TriSalus Life Sciences® Inc., (NASDAQ:TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced delivery technology and novel immunotherapy, nelitolimod, announced today it will host a conference call and webcast on November 14, 2024, at 9:00 a.m. ET to discuss financial results for the third quarter ended September 30, 2024, and provide a business update. A press release detailing the third quarter results will be issued prior to the call. The event will be webcast live on the investor relations section of TriSalus' website at https://investors.trisaluslifes

TriSalus Life Sciences® Inc. ("TriSalus" or the "Company") (NASDAQ:TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced delivery technology and novel immunotherapy, nelitolimod, announced today that Mary Szela, Chief Executive Officer and President of TriSalus, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Thursday, October 17, 2024. Details for the fireside chat are as follows: Date: Thursday, October 17, 2024 Time: 12:30 p.m. EDT / 11:30 a.m. CDT Presenter: Mary Szela, Chief Executive Officer and President of TriSalus To attend the event, please register by clicking here. For

TriSalus Life Sciences® Inc. ("TriSalus" or the "Company") (NASDAQ:TLSI), an oncology company dedicated to enhancing outcomes for patients with liver and pancreatic cancer through its advanced delivery technology and novel immunotherapy, nelitolimod, has announced the addition of Riad Salem, M.D., to its Scientific Advisory Board (SAB). Dr. Salem is the Chief of Interventional Radiology, and a Professor of Radiology, Surgery, and Medicine in Chicago. Mary Szela, Chief Executive Officer and President of TriSalus, stated, "We are thrilled to welcome Dr. Salem to our SAB. His pioneering work in radiological research and leadership in developing innovative treatments for liver cancer and other

Pressure enabled drug deliver (PEDD) method significantly increased penetration of glass microspheres into porcine liver tumors (117%; p=0.004 and 39%; p=0.032) with lobar infusions and selective infusions, respectively TriSalus Life Sciences®, Inc. ("TriSalus" or the "Company") (NASDAQ:TLSI), an oncology company integrating its novel delivery technology with standard of care therapies and immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today the publication of research titled, "Intra-arterial Pressure-Enabled Drug Delivery Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model," in the peer-reviewed Journal of

Reported revenues of $7.4 million in Q2 2024 and $13.8 million for six months ended June 30, 2024, up 60% and 82%, respectively, compared to prior year periods Reported gross margin of 88% in Q2 2024 and 86% for the six months ended June 30, 2024, compared to 83% and 81%, respectively, in the prior year periods Announces plan to launch the "DELIVER" Program in Q3 2024, clinical trials leveraging the TriNav® Infusion System (TriNav) in complex patient types and aiming to significantly expand the addressable market Expects to report data from phase 1 trials of nelitolimod in uveal melanoma liver metastases and locally advanced pancreatic cancer via its pancreatic infusion technol

Call Scheduled for Thursday, August 15, 2024, at 9:00 a.m. ET TriSalus Life Sciences® Inc., (NASDAQ:TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today it will host a conference call and webcast on August 15, 2024, at 9:00 a.m. ET to discuss financial results for the second quarter ended June 30, 2024, and provide a business update. A press release detailing the second quarter results will be issued prior to the call. The event will be webcast live on the investor relations section of TriSalus' website at https://investors.trisaluslifesci.com/news-events/events-prese

TriSalus Life Sciences® Inc. ("TriSalus" or the "Company") (NASDAQ:TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today the closing of its previously announced exchange offer (the "Offer") and consent solicitation (the "Consent Solicitation") relating to its warrants (the "Warrants") identified in the Prospectus/Offer to Exchange that forms a part of the Registration Statement (as defined below). The Company issued 2,110,366 shares of the Company's common stock, par value $0.0001 per share ("Common Stock"), in exchange for the Warrants tendered in the Offer. As previous

10-Q - TriSalus Life Sciences, Inc. (0001826667) (Filer)

8-K - TriSalus Life Sciences, Inc. (0001826667) (Filer)

EFFECT - TriSalus Life Sciences, Inc. (0001826667) (Filer)

EFFECT - TriSalus Life Sciences, Inc. (0001826667) (Filer)

POS AM - TriSalus Life Sciences, Inc. (0001826667) (Filer)

8-K - TriSalus Life Sciences, Inc. (0001826667) (Filer)

S-3 - TriSalus Life Sciences, Inc. (0001826667) (Filer)

POS AM - TriSalus Life Sciences, Inc. (0001826667) (Filer)

POS AM - TriSalus Life Sciences, Inc. (0001826667) (Filer)

POS AM - TriSalus Life Sciences, Inc. (0001826667) (Filer)

Canaccord Genuity analyst William Plovanic maintains TriSalus Life Sciences (NASDAQ:TLSI) with a Buy and maintains $12 price target.

TriSalus Life Sciences, Inc. (NASDAQ:TLSI), an oncology company integrating its novel Pressure Enabled Drug Delivery™ (PEDD™) technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced that data from its Phase 1b PERIO-02 clinical trial was presented in a poster session at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, taking place May 31-June 4, 2024, in Chicago, Illinois. The PEDD approach is a proprietary delivery mechanism developed by TriSalus that aims to overcome challenges of the tumor microenvironment (TME) by modulating pressure and flow to enhance local drug concentrations in tumors by improving intra

Canaccord Genuity analyst William Plovanic initiates coverage on TriSalus Life Sciences (NASDAQ:TLSI) with a Buy rating and announces Price Target of $12.

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 1% on Friday. The Dow traded up 0.12% to 39,112.74 while the NASDAQ rose 1.08% to 16,917.09. The S&P 500 also rose, gaining, 0.70% to 5,304.78. Check This Out: Top 3 Health Care Stocks That May Crash In May Leading and Lagging SectorsCommunication services shares jumped by 1.3% on Friday. In trading on Friday, health care shares fell by 0.1%. Top Headline The total number of active U.S. oil rigs came in unchanged at 497 rigs this week, Baker Hughes Inc reported. Equities Trading UP                        Akanda Corp. (NASDAQ:AKAN) shares shot up 34% to $3.2001. The inter

Shares of NetEase, Inc. (NASDAQ:NTES) fell during Friday's session after the company reported worse-than-expected first-quarter revenue. NetEase reported fiscal first-quarter 2024 revenue growth of 7.2% year-on-year to $3.72 billion (26.9 billion Chinese yuan), missing the analyst consensus estimate of $3.79 billion. The Chinese gaming player’s adjusted EPADS of $1.81 beat the analyst consensus estimate of $1.79, according to data from Benzinga Pro. NetEase shares declined 4% to $91.02 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Akanda Corp. (NASDAQ:AKAN) shares climbed 101% to $4.81. The international medical cannabis company implemented

Gainers Innovative Eyewear (NASDAQ:LUCY) shares increased by 328.8% to $0.8 during Friday's regular session. The market value of their outstanding shares is at $13.9 million. OneMedNet (NASDAQ:ONMD) shares increased by 66.66% to $2.45. The market value of their outstanding shares is at $58.4 million. TransCode Therapeutics (NASDAQ:RNAZ) stock rose 28.05% to $1.78. The company's market cap stands at $11.7 million. Onconetix (NASDAQ:ONCO) shares moved upwards by 20.15% to $0.17. The market value of their outstanding shares is at $3.7 million. The company's, Q1 earnings came out 4 days ago. Aptorum Gr (NASDAQ:APM) shares moved upwards by 17.2% to $4.7. The market value of their outstanding

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 1% on Friday. The Dow traded up 0.25% to 39,163.18 while the NASDAQ rose 1.04% to 16,909.33. The S&P 500 also rose, gaining, 0.69% to 5,304.30. Check This Out: Top 3 Health Care Stocks That May Crash In May Leading and Lagging SectorsCommunication services shares jumped by 1.1% on Friday. In trading on Friday, health care shares fell by 0.1%. Top Headline Shares of Intuit Inc. (NASDAQ:INTU) fell around 8% on Friday following third-quarter results. The company posted better-than-expected earnings for its third quarter and boosted its full-year outlook. However, the company issued w

TriSalus Life Sciences (NASDAQ:TLSI) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate of $(0.65) by 7.69 percent. This is a 5.26 percent decrease over losses of $(0.57) per share from the same period last year. The company reported quarterly sales of $6.457 million which beat the analyst consensus estimate of $6.178 million by 4.51 percent. This is a 116.39 percent increase over sales of $2.984 million the same period last year.

JonesTrading analyst Justin Walsh initiates coverage on TriSalus Life Sciences (NASDAQ:TLSI) with a Buy rating and announces Price Target of $16.

$25 million funded at close; up to $25 million of additional capital available at the Company's option, based on the achievement of certain revenue thresholdsCapital from the transaction is expected to support execution of strategic expansion and fuel continued growthIncluding the full funding of this facility, along with current cash and cash equivalents on hand, the Company expects its cash runway to extend through 2025TriSalus Life Sciences Inc., (NASDAQ:TLSI), today announced the closing of a debt financing facility for up to $50 million with OrbiMed, a healthcare investment firm. The capital is expected to provide financial flexibility to support the execution of strategic expansion pla